JW (Cayman) Therapeutics Co. Ltd (stock code: 02126) reported that its total authorized share capital remains at US$50,000, comprising 5,000,000,000 ordinary shares with a par value of US$0.00001 each. The number of issued shares was unchanged at 416,473,250, and the company confirmed compliance with the 25% public float requirement.

No changes occurred in treasury shares, and no new shares were issued through warrants or convertibles. Under existing share option plans, 193,870 options lapsed in January 2026 (Post-IPO Incentivization Scheme (vii)), and an additional 1,500,000 lapsed under Post-IPO Incentivization Scheme (viii). Meanwhile, a new grant of 2,600,000 options with an exercise price of HK$2.92 was made under Post-IPO Incentivization Scheme (ix). At the close of the reporting period, 2,456,183 options remained available under plan (viii).

According to the filing, 1,195,666 potential shares may be issued under the Restricted Share Unit Scheme adopted on September 4, 2019, and no unit conversions took place during the reporting month.